166 related articles for article (PubMed ID: 35255452)
1. Precision medicine for rare diseases: The times they are A-Changin'.
Amaral MD
Curr Opin Pharmacol; 2022 Apr; 63():102201. PubMed ID: 35255452
[TBL] [Abstract][Full Text] [Related]
2. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
3. Orphan drug clinical development.
Blin O; Lefebvre MN; Rascol O; Micallef J
Therapie; 2020 Apr; 75(2):141-147. PubMed ID: 32247678
[TBL] [Abstract][Full Text] [Related]
4. Development of precision therapies for rare inborn errors of metabolism: Functional investigations in cell culture models.
Didiasova M; Banning A; Tikkanen R
J Inherit Metab Dis; 2024 May; 47(3):509-516. PubMed ID: 37606592
[TBL] [Abstract][Full Text] [Related]
5. 10th World Orphan Drug Congress (WODC) (November 12-14, 2019 - Barcelona, Spain).
Künnemann K
Drugs Today (Barc); 2019 Dec; 55(12):753-758. PubMed ID: 31942878
[TBL] [Abstract][Full Text] [Related]
6. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
7. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
8. Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?
Brasil S; Pascoal C; Francisco R; Dos Reis Ferreira V; Videira PA; Valadão AG
Genes (Basel); 2019 Nov; 10(12):. PubMed ID: 31783696
[TBL] [Abstract][Full Text] [Related]
9. Orphan Drugs in Oncology.
Korchagina D; Jaroslawski S; Jadot G; Toumi M
Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
[TBL] [Abstract][Full Text] [Related]
10. Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions.
Auvin S; Avbersek A; Bast T; Chiron C; Guerrini R; Kaminski RM; Lagae L; Muglia P; Cross JH
Drugs; 2019 Dec; 79(18):1917-1935. PubMed ID: 31734883
[TBL] [Abstract][Full Text] [Related]
11. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
12. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
13. Precision Medicines' Impact on Orphan Drug Designation.
Mueller CM; Rao GR; Miller Needleman KI
Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
[TBL] [Abstract][Full Text] [Related]
14. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Micallef J; Blin O
Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
[TBL] [Abstract][Full Text] [Related]
15. The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development.
Heslop E; Csimma C; Straub V; McCall J; Nagaraju K; Wagner KR; Caizergues D; Korinthenberg R; Flanigan KM; Kaufmann P; McNeil E; Mendell J; Hesterlee S; Wells DJ; Bushby K;
Orphanet J Rare Dis; 2015 Apr; 10():49. PubMed ID: 25902795
[TBL] [Abstract][Full Text] [Related]
16. Orphan Drugs and Their Impact on Pharmaceutical Development.
Attwood MM; Rask-Andersen M; Schiöth HB
Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
Micallef J; Boutouyrie P; Blin O
Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
[TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing for Rare Diseases.
Roessler HI; Knoers NVAM; van Haelst MM; van Haaften G
Trends Pharmacol Sci; 2021 Apr; 42(4):255-267. PubMed ID: 33563480
[TBL] [Abstract][Full Text] [Related]
19. Drug repositioning for orphan diseases.
Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
[TBL] [Abstract][Full Text] [Related]
20. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
